Condition 1: Acute lymphoblastic leukemia (ALL). Condition 2: Chronic lymphocytic leukemia (CLL). Acute lymphoblastic leukaemia Chronic lymphocytic leukaemia
Conditions
Interventions
Injecting 29 * 106 /kg NK cells to patients with leukemia Intravenously and then Injection of Repetitive doses of IL-2 (6 doses) subcutaneously to stimulate the proliferation and activation of NK-posi
Treatment - Other
Sponsors
Stem Cell And Regenerative Medicine Institute
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1-Age range of 18- 25 years for ALL patients; 2-Age range over 50 years for patients with CLL; 3- Those who have a proper cell donors with incongruent KIR (Haploidentical KIR-L mismatched donor); 4- Patients with adequate organ function; 5-Access to the patient for the continuation of treatment and follow-up (preferably from Azeri-speaking patients for easier access and removal of the Zentique variable); Exclusion criteria : 1-Patients with active and uncontrolled infections; 2-Abnormal kidney, lung and liver function, measured by serum creatinine (serum creatinine> 2 mg / dl), saturated oxygen O2 = 96%) (Sat and liver enzymes (ALT / AST> 2.5 x N); 3-Patients with Down syndrome; 4- Patients with acute promyelocytic leukemia
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phenotype and function of NK cells. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| IFN?. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry.;CD107. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeili Aghebati Maleki
Stem Cell And Regenerative Medicine Institute
Outcome results
None listed